Vaccine News and Research

Latest Vaccine News and Research

Sanofi Pasteur submits supplemental application for influenza A(H1N1) 2009 monovalent vaccine to FDA

Sanofi Pasteur announced today the company has submitted to the U.S. Food and Drug Administration (FDA) a supplemental application for licensure of its influenza A(H1N1) 2009 monovalent vaccine.

7 Aug 2009

Updated Federal Guidelines for 2009 H1N1 influenza in schools

Updated federal guidelines offer state and local public health and school officials a range of options for responding to 2009 H1N1 influenza in schools, depending on how severe the flu may be in their communities.

7 Aug 2009

Novel approach for developing an AIDS vaccine

Researchers at the Yerkes National Primate Research Center, Emory University, believe conventional vaccine strategies should not be the only avenue explored in the development of an effective AIDS vaccine.

7 Aug 2009

H1N1 vaccine will be approved, ready for use by September, WHO says

By September, the first H1N1 (swine) flu vaccines will be approved and ready for use, WHO director of the Initiative for Vaccine Research Marie-Paule Kieny said Thursday, Reuters reports. Kieny also expressed optimism that "vaccine production yields were improving, following a disappointing start that triggered some worries about supplies," the news service writes.

7 Aug 2009

Scientists find key to strengthening immune response to chronic infection

A team of researchers from The Wistar Institute has identified a protein that could serve as a target for reprogramming immune system cells exhausted by exposure to chronic viral infection into more effective "soldiers" against certain viruses like HIV, hepatitis C, and hepatitis B, as well as some cancers, such as melanoma.

6 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Automated network could predict disease outbreaks that originate in animals

The AP/San Francisco Chronicle examines Los Alamos National Laboratory researchers' efforts to create an automated network to monitor animals in an effort to predict disease outbreaks because two out of every three human diseases "originated in animals."

6 Aug 2009

Fast-tracked H1N1 vaccines will not compromise safety, WHO says

Efforts to fast-track the approval of H1N1 (swine) flu vaccines will not compromise the safety or quality controls of vaccine production, the WHO said in a written statement Thursday, the Mail & Guardian reports.

6 Aug 2009

Bloomberg examines China plague cases, potential for disease spread

"Plague-spreading fleas are expanding their territory, putting more people at risk of catching the lethal illness, a WHO official said," Bloomberg reports, in an article that examines the recent deaths of three people in China from the pneumonic plague.

6 Aug 2009

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Ichor Medical Systems awarded $3.3 million to develop Alzheimer’s vaccine

Ichor Medical Systems of San Diego has announced that it has been selected to receive a $3.3 million grant award from the National Institute of Neurological Disorders and Stroke (NINDS) for development of a vaccine for Alzheimer’s disease.

6 Aug 2009

More than half of Texas physicians do not follow HPV recommendations

The Advisory Committee on Immunization Practices recommends the human papillomavirus vaccination for all 11- and 12-year-old girls, but results of a recent survey showed that more than half of Texas physicians do not follow these recommendations.

6 Aug 2009

Take Care Health Systems now offering nebulizer treatments for acute respiratory distress

Take Care Health Systems is now offering nebulizer treatments, when clinically appropriate, for clinic patients exhibiting acute respiratory distress.

6 Aug 2009

2 billion worldwide could het H1N1, says WHO

The WHO on Tuesday maintained that roughly two billion people could become infected with the H1N1 (swine flu) virus, Reuters reports.

6 Aug 2009

States confront budget pressure, anticipate reform

States are grappling with budget cuts, trying to anticipate the effects of Washington's health system overhaul and rejiggering Medicaid programs.

5 Aug 2009

Baxter completes production of batches of CELVAPAN A/H1N1 pandemic vaccine

Baxter International Inc. (NYSE: BAX) today announced that it completed production of its first commercial batches of CELVAPAN A/H1N1 pandemic vaccine in late July and is discussing plans for distribution with national health authorities, subject to obtaining appropriate authorizations. CELVAPAN, the brand name for the company’s A/H1N1 pandemic influenza vaccine, is made using Baxter’s proprietary Vero cell culture technology.

From Baxter International Inc. 5 Aug 2009

Iowa funds swine vaccine research

A grant from a state economic development fund will help Iowa State University researchers develop and evaluate a vaccine designed to protect swine from novel H1N1 and other strains of influenza.

5 Aug 2009

Discovery of potential candidate protein for cancer vaccines

Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers. The finding suggests that a vaccine against the protein might prevent malignancies in high-risk individuals.

4 Aug 2009

Evidence of Malaria origins, could lead to vaccine development

"Malaria may have jumped to humans from chimpanzees much as AIDS did, U.S. researchers reported on Monday in a [Proceedings of the National Academy of Sciences] study they hope could help in developing a vaccine against the infection," Reuters reports.

4 Aug 2009